Regenerative Medicine Innovation Projects (RMIP) Investigator-Initiated Studies (Collaborative U01 Clinical Trial Not Allowed)
Closed Posted
- Opportunity number
- RFA-HL-18-030
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.121 Oral Diseases and Disorders Research
- 93.173 Research Related to Deafness and Communication Disorders
- 93.233 National Center on Sleep Disorders Research
- 93.242 Mental Health Research Grants
- 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health
- 93.350 National Center for Advancing Translational Sciences
- 93.837 Cardiovascular Diseases Research
- 93.838 Lung Diseases Research
- 93.839 Blood Diseases and Resources Research
- 93.840 Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
- Funding instrument
- Cooperative Agreement
- Categories
-
- Food and Nutrition
- Health
- Eligible applicants
-
- Small Businesses
- State Governments
- Tribal Governments (Federally Recognized)
- Non-501(c)(3) Nonprofits
- 501(c)(3) Nonprofits
- Other
- For Profit Organizations
- Independent School Districts
- County Governments
- Higher Education Inst. (Public)
- Public or Indian Housing Auth.
- City/Township Governments
- Tribal Organizations (Not Federally Recognized)
- Higher Education Inst. (Private)
- Special District Governments
- Full announcement
Opportunity details come from Grants.gov. Updated .
Synopsis
The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U01) applications to support investigator-initiated clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of in-depth product characterization, manufacturing, potency, identity, quality, safety, in vivo function and integration, or effectiveness. Toward these ends, the NIH will consider applications for late-stage preclinical research studies involving adult stem cells in the context of generating or supplementing the necessary evidence for clinical development, including, but not limited to, the submission of an Investigational New Drug (IND) or Investigational New Device Exemption (IDE) package; or to support such research conducted under an authorized IND or IDE.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Files
| File | Type | Posted |
|---|---|---|
| oppRFA-HL-18-030-cidFORMS-E-instructions.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity